Medical Condition News

RSS

Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint

Bayer HealthCare Pharmaceuticals Inc. today announced that the Phase III ALSYMPCA trial evaluating Bayer's investigational compound, radium-223 chloride, which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and bone metastases met its primary endpoint by significantly improving overall survival.

6 Jun 2011

Topiramate drug can help people lose weight

The drug topiramate can help people lose weight as long as they can tolerate the side effects, according to authors of a new study that reviewed the medical literature. Brazilian researchers will present the results Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation at the ASCO 2011 Annual Meeting in Chicago.

6 Jun 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Incyte Corporation announced today results from the global, pivotal Phase III clinical program of ruxolitinib in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.

6 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Ipsen decides to assess development of Irosustat in combination with hormonal therapies

Ipsen today announced its decision to assess the alternative development of Irosustat (BN 83495) in combination with other hormonal therapies. This decision is based on the futility analysis from the proof-of-concept trial phase II clinical study carried out in Europe in monotherapy in endometrial cancer, and on the phase I/II clinical study results obtained in metastatic prostate and breast cancers.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

ImaginAb, GE Healthcare sign master research deal to develop new PET diagnostic imaging agents

GE Healthcare Ltd. and ImaginAb, Inc. have executed a master research agreement around the development of new PET (Positron Emission Tomography) diagnostic imaging agents based on ImaginAb's antibody fragment technology. The agreement is launched with an initial exclusive collaboration around a novel cardiovascular target.

6 Jun 2011

GP journal focuses on mental health

Australian Family Physician, the flagship journal of The Royal Australian College of General Practitioners (RACGP), features a range of clinical, viewpoint and research articles focusing on key issues in general practice today. The June 2011 edition focuses on mental illness and includes the following feature articles.

6 Jun 2011

Older adults with subclinical hyperthyroidism may face higher risk of dying

A common hormone abnormality in older adults—a mild form of overactive thyroid called subclinical hyperthyroidism—is linked to a much higher risk of dying, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the presentation of favorable clinical data for SAR3419 in the treatment of B-cell non-Hodgkin's lymphoma (NHL).

6 Jun 2011

Brown fat can treat obesity and diabetes

A new study suggests that many adults have large amounts of brown fat, the "good" fat that burns calories to keep us warm, and that it may be possible to make even more of this tissue.

6 Jun 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

6 Jun 2011

Nonmenstruating female athletes have abnormal bone structure: Study

Young female athletes who have stopped menstruating have a weakening in the quality of their bone structure that may predispose them to breaking a bone, despite getting plenty of weight-bearing exercise, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

$Bariatric weight-loss surgery may increase risk of fractures$

Bariatric weight-loss surgery may increase risk of fractures

People who have had gastric bypass surgery or other bariatric weight-loss surgery have an even higher increased risk of breaking bones than previously found. These study findings will be presented Tuesday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Anti-ghrelin vaccine decreases food intake and increases calorie burning in mice

A new therapeutic vaccine to treat obesity by suppressing the appetite-stimulating hormone ghrelin decreases food intake and increases calorie burning in mice, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced efficacy and safety data from the BRIM3 trial, a large, randomized, multi-center Phase 3 clinical study of vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation.

6 Jun 2011

Wrinkles and bone health: Connection

According to a new study, women who have severe skin wrinkles during the first few years of menopause also appear to have lower bone mineral density.

5 Jun 2011

Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

Customizing targeted therapies to each tumor's molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research conducted by The University of Texas MD Anderson Cancer Center.

4 Jun 2011

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Sanofi US announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%, meeting the study primary endpoint.

4 Jun 2011

Medical Condition News

Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint

Topiramate drug can help people lose weight

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Ipsen decides to assess development of Irosustat in combination with hormonal therapies

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

ImaginAb, GE Healthcare sign master research deal to develop new PET diagnostic imaging agents

GP journal focuses on mental health

Older adults with subclinical hyperthyroidism may face higher risk of dying

ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011

Brown fat can treat obesity and diabetes

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Nonmenstruating female athletes have abnormal bone structure: Study

Bariatric weight-loss surgery may increase risk of fractures

Anti-ghrelin vaccine decreases food intake and increases calorie burning in mice

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Wrinkles and bone health: Connection

Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Latest News